LaNeo Product Data submitted for a Clinical Trial in CanadaTORONTO, March 26, 2024 (GLOBE NEWSWIRE) PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA, OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to announce that it had entered into a binding sales agreement with Numinus Wellness Inc. (“Numinus”) (TSX: NUMI, OTCQX: NUMIF) to provide its GMP LaNeo
Scientific Journal Article follows notable IP updates, including publication of key PCT Patent Application, presentation at International Society for Research into Psychedelics ConferenceVANCOUVER, British Columbia, Feb. 20, 2024 (GLOBE NEWSWIRE) PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased that